Stock analysts at William Blair raised their Q3 2025 earnings per share estimates for AZEK in a research note issued on ...

A city man is behind bars after allegedly pointing a loaded gun at his wife’s head and then fighting officers when they arrived. William Edward Desch III, 55, was arraigned Sunday by Magisterial ...

Axsome settles Auvelity patent litigation with Teva, delaying a generic launch until 2038. Analysts see growth potential with Symbravo's migraine approval.

William Blair reaffirmed their market perform rating on shares of Viasat (NASDAQ:VSAT – Free Report) in a report published on Friday morning,RTT News reports. Several other equities analysts have also ...

William Blair reaffirmed a Market Perform rating on Kenvue Inc (NYSE:KVUE), a consumer health company with a market capitalization of $38.69 billion. According to InvestingPro data, the company ...

William Blair reiterated a Market Perform rating on CBOE Holdings (NYSE:CBOE), following the company's latest earnings report. CBOE Holdings reported an adjusted EPS of $2.10, falling short of both ...

William Blair, the premier global boutique with expertise in investment banking, investment management, and private wealth management, has named managing directors John Ivey and B.T. Remmert as the ...

Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...

For investors looking for opportunities in fintech, SoFi presents an interesting case. Here's where analysts think the stock ...

The buy now/pay later lender outperformed nearly every analyst estimate in its fiscal Q2 2025 earnings report. CEO Max Levchin said the company is 5 months out from positive GAAP operating income.

Neurocrine Biosciences Q4 earnings topped forecasts, but revenue slightly missed. Analysts see Ingrezza's long-term growth ...